For more information, availability and pricing options for sponsorship/exhibition opportunities at the event, please contact Jon Liong at firstname.lastname@example.org.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$15 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 200 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OAP has made PE investments in 29 companies, with close to USD$500 million under management. OrbiMed has also invested over USD$1 billion in the stocks of Asia public healthcare companies. For More information, please vist www.orbimed.com.
The ECCRT is a specialised clinical research training organisation focusing on the transfer of implementable knowledge in the day-to-day activities of our participants whether being starters on the job or seasoned professionals.
Our mission is to facilitate Clinical Researchers to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new treatments for patients more efficient, without jeopardizing quality.
The ECCRT is in its actions supportive of the Benjamin Franklin's statement: “You tell me, and I forget. You teach me, and I remember. You involve me, and I learn.”
PRA HEALTH SCIENCES
PRA has been delivering innovative drug development solutions in China for nearly a decade and continue that work through our locations in Beijing, Shanghái and Dalian.
We strive to move drug discovery forward side-by-side with our clients, helping them to develop live-saving and life-improving drugs. We provide comprehensive clinical development and data services across all phases with our unique blend of expertise and technology. From full-service clinical development to our pioneering Embedded Solutions™ model, PRA offers a broad spectrum of solutions that meet the demands of a diverse marketplace.
As a top five CRO, we have worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of more than 75 such drugs.
PRA provides the local and global presence you need, with 15,500+ employees covering over 85 countries, combined with an in-depth knowledge of local regulations, standards of care, and the cultural customs our clients expect.
Our mission in China is to build the most comprehensive and flexible offering to support our clients with global trials, embedded teams, in-house biometrics, and local trials in China.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 60 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 3200 full time staffs. Tigermed has set up international standard SOPs and serviced more than 600 local and global clients in the conduct of over 920 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 130 innovative drugs.
For more information about Tigermed, please visit www.tigermed.net